In personalized medicine, the patient is the process is the product.(TM)
Backed by GE Ventures, Mayo Clinic Ventures, and DFJ, the Vineti team brings together a hybrid of experts in user-centric, regulated industry software and analytics development, as well as commercial therapeutics development and manufacturing.
Uniting all of us is a belief that we are transitioning from one-size-fits-all medicine to individualized therapies as the standard of care. To achieve the full potential of this vision, Vineti is working to build technologies that support therapeutic development and delivery and keep pace with the leading therapeutic science. Together with our leading pharmaceutical partners, we are doing just that with our independent Vineti solution.
What is the thinking behind our name? Vineti is an ancient term of wisdom that invokes the idea of progress by removing obstacles and guiding towards a goal.
Before co-founding Vineti, Amy focused on healthcare new business creation for GE Ventures/ healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was co-founder and Executive Director of Proposition 71, California’s $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Amy holds an MBA and MA/BA in English from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute.
Heidi has been an Operations Executive in the Biotechnology industry for over 25 years and is a Co-founder of Vineti. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. Previously, Heidi was the Global COO for SOTIO, in Prague, Czech Republic with a US office in Boston, MA. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations and ten years with Immunex Corporation in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.
Razmik is a leading business software executive. He is currently a consultant and co-founder at Vineti, and served as the company’s founding CEO. He is also the former CTO for the EMC Documentum product family, a leading enterprise content management platform providing solutions for Fortune 500 companies. Razmik was one of the original designers of the Documentum platform. He was also a founding member of the Documentum team and helped grow it to become a leading force in the enterprise content management industry, with an IPO in 1996 and eventual acquisition by EMC in 2003 for $1.7 billion. Razmik is the author of several patents and co-author of several technical books. He is also an investor and advisor to multiple high-tech companies.
Khurram, currently CTO at Vineti, is an experienced technology leader and entrepreneur with close to 20 years of experience leading engineering and product management organizations at enterprise software companies such as Workday, Oracle, and PeopleSoft. Most recently he was at Workday, where he joined the company when it was a small startup with a handful of people. Khurram helped scale the company to one of the leading enterprise cloud companies in the world. Khurram has earned several innovation awards and also holds several technology patents. He holds a BA with honors in Computer Science, Economics, and Mathematics from the University of Texas at Austin, and an MS in Computer Science with a concentration in Software Engineering from Carnegie Mellon University.
Dr. Malek Faham is a scientific advisor and co-founder of Vineti. He was formerly co-founder and CSO of Sequenta Inc, where he led technology development, scientific direction, clinical validation, and operation from the initial vision in 2008 of the potential of immune receptor repertoire sequencing to the company’s acquisition in 2015 by Adaptive Biotechnologies. Previously, Dr. Faham co-founded Parallele Bioscience, Inc. in 2001 and served as its Director for Research until its acquisition by Affymetrix in 2005. He then served as VP of Oncology Technology Research at Affymetrix until 2008. He has published more than 50 peer-reviewed articles and has over 100 issued and pending patents. Dr. Faham received his MD, Ph.D. in biochemistry and human genetics and Psychiatry residency training from University of California San Francisco, and completed his post-doctoral training with Professor Ronald W. Davis in the Stanford Genome Technology Center.
April has been a leader in biotechnology and healthcare for more than a decade. She has a proven track record in product and market strategies, communications, and making biotechnology innovations accessible, scalable, and engaging. Before joining Vineti, April led an innovations team at Invitae, a genetic information company, and also served as Invitae’s head of Product. She previously worked in product strategy and product marketing for Life Technologies, focusing on genomic diagnostic analysis in cancer, and for Navigenics, a pioneering personal genomics start-up. Before starting her work in biotech, April was an award-winning journalist, author, and editor, with hundreds of articles and a series of university textbooks published under her byline. She has a BA from Pomona College and an MA in journalism and communications from the University of California at Berkeley.
Tamie has focused on cell and gene therapy clinical trial logistics, commercialization & patient hub services strategies for over 15 years. She is an expert in the lifecycle of specialty pharmaceuticals and the challenges posed by patient-centric distribution, REMS compliance, value-based reimbursement strategies and specialized patient hub services. As an executive at AmerisourceBergen Specialty Group, PAREXEL, and Cryoport, she has led teams that have: developed distribution and hub service strategies, provider education, and REMS requirements; led global business development & project management for trials in 140+ countries; supported logistics for over 120 cell and gene therapy clinical trials. Tamie started her career as an accountant with Arthur Andersen & Co. and provided manufacturing, inventory control & distribution IT consulting services. She holds degrees in accounting and computer science from East Central University in Oklahoma.
Marc focuses on leading the global sales activities for the Vineti Platform. Prior to joining Vineti Marc, held various positions at Werum IT Solutions, the leading provider of Manufacturing Execution Systems for the Pharmaceutical Industry. There, he was directly involved with sales and implementation of Werum’s PAS-X MES, as well as supporting organizations as they continued to drive benefits post go-live. Marc came to Werum with ten years consulting experience as a partner focused on the pharmaceutical and biotech sectors at Tefen USA. He holds a Bachelor’s in Physics from UC Berkeley and Master’s degree in Industrial Engineering and Engineering Management from Stanford University.